JPM 24: How Takeda beat 'almost every biopharmaceutical company' to win Nimbus’ TYK2 med

Takeda turned heads at the tail end of 2022 when it announced a $4 billion acquisition of Nimbus Therapeutics’ tyrosine kinase 2 med, now known as TAK-279, throwing the Japanese company squarely in the middle of a hotly-contested immunology battle with Bristol Myers Squibb’s Sotyktu.